协和研究：一项关于新型药物与传统放疗联合用于非小细胞肺癌的I期平台研究。
CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.
作者信息
Walls Gerard M, Oughton Jamie B, Chalmers Anthony J, Brown Sarah, Collinson Fiona, Forster Martin D, Franks Kevin N, Gilbert Alexandra, Hanna Gerard G, Hannaway Nicola, Harrow Stephen, Haswell Tom, Hiley Crispin T, Hinsley Samantha, Krebs Matthew, Murden Geraldine, Phillip Rachel, Ryan Anderson J, Salem Ahmed, Sebag-Montefoire David, Shaw Paul, Twelves Chris J, Walker Katrina, Young Robin J, Faivre-Finn Corinne, Greystoke Alastair
机构信息
Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland, UK.
Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.
出版信息
Clin Transl Radiat Oncol. 2020 Sep 22;25:61-66. doi: 10.1016/j.ctro.2020.09.006. eCollection 2020 Nov.
Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.
肺癌是全球癌症死亡的主要原因，大多数患者不适合采用“金标准”治疗，即同步放化疗。CONCORDE是一项平台研究，旨在确定在接受序贯放化疗的患者中，多种针对DNA修复蛋白的新型放射增敏剂的毒性特征。事件发生时间的连续重新评估将有助于高效的剂量探索。
Zotero 插件